{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:34:16Z","timestamp":1721882056122},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamadermatol.2021.5172","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:33:41Z","timestamp":1640190821000},"page":"217","source":"Crossref","is-referenced-by-count":4,"title":["Chilblains and COVID-19\u2014An Update on the Complexities of Interpreting Antibody Test Results, the Role of Interferon \u03b1, and COVID-19 Vaccines"],"prefix":"10.1001","volume":"158","author":[{"given":"Qisi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther E.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"8","key":"dle210007r1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamadermatol.2021.2120","article-title":"Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic.","volume":"157","author":"McCleskey","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"dle210007r2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamadermatol.2020.4324","article-title":"Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic.","volume":"157","author":"Hubiche","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10","key":"dle210007r3","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1111\/jdv.v35.10","article-title":"Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that \u2018COVID toes\u2019 are due to the immune reaction to SARS-CoV-2.","volume":"35","author":"Lesort","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"31","key":"dle210007r4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3409","article-title":"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.","volume":"7","author":"Peluso","year":"2021","journal-title":"Sci Adv"},{"issue":"11","key":"dle210007r5","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/jdv.v34.11","article-title":"A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection.","volume":"34","author":"El Hachem","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2787466\/jamadermatology_sun_2021_le_210007_1643827846.94514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:07:11Z","timestamp":1645027631000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2787466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.5172","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}